Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015 (2015), Article ID 785634, 18 pages
http://dx.doi.org/10.1155/2015/785634
Review Article

Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, 1090 Brussels, Belgium

Received 28 February 2015; Revised 26 August 2015; Accepted 3 September 2015

Academic Editor: David E. Gilham

Copyright © 2015 Cleo Goyvaerts and Karine Breckpot. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Breckpot, C. Heirman, B. Neyns, and K. Thielemans, “Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells,” Journal of Gene Medicine, vol. 6, no. 11, pp. 1175–1188, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. K. F. Bol, J. Tel, I. J. M. de Vries, and C. G. Figdor, “Naturally circulating dendritic cells to vaccinate cancer patients,” OncoImmunology, vol. 2, no. 3, Article ID e23431, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Shortman, M. H. Lahoud, and I. Caminschi, “Improving vaccines by targeting antigens to dendritic cells,” Experimental and Molecular Medicine, vol. 41, no. 2, pp. 61–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Goyvaerts, K. De Groeve, J. Dingemans et al., “Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells,” Gene Therapy, vol. 19, no. 12, pp. 1133–1140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Yang, H. Yang, K. Rideout et al., “Engineered lentivector targeting of dendritic cells for in vivo immunization,” Nature Biotechnology, vol. 26, no. 3, pp. 326–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Sehgal, K. M. Dhodapkar, and M. V. Dhodapkar, “Targeting human dendritic cells in situ to improve vaccines,” Immunology Letters, vol. 162, no. 1, pp. 59–67, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Arce, K. Breckpot, M. Collins, and D. Escors, “Targeting lentiviral vectors for cancer immunotherapy,” Current Cancer Therapy Reviews, vol. 7, no. 4, pp. 248–260, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Apostolopoulos, T. Thalhammer, A. G. Tzakos, and L. Stojanovska, “Targeting antigens to dendritic cell receptors for vaccine development,” Journal of Drug Delivery, vol. 2013, Article ID 869718, 22 pages, 2013. View at Publisher · View at Google Scholar
  9. N. Bhardwaj, J. W. Young, A. J. Nisanian, J. Baggers, and R. M. Steinman, “Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses,” The Journal of Experimental Medicine, vol. 178, no. 2, pp. 633–642, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. R. M. Steinman and Z. A. Cohn, “Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution,” The Journal of Experimental Medicine, vol. 137, no. 5, pp. 1142–1162, 1973. View at Publisher · View at Google Scholar
  11. D. Dudziak, A. O. Kamphorst, G. F. Heidkamp et al., “Differential antigen processing by dendritic cell subsets in vivo,” Science, vol. 315, no. 5808, pp. 107–111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. S. Allan, J. Waithman, S. Bedoui et al., “Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming,” Immunity, vol. 25, no. 1, pp. 153–162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. L. M. Wakim and M. J. Bevan, “Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection,” Nature, vol. 471, no. 7340, pp. 629–632, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Coquerelle and M. Moser, “DC subsets in positive and negative regulation of immunity,” Immunological Reviews, vol. 234, no. 1, pp. 317–334, 2010. View at Publisher · View at Google Scholar
  15. K. Breckpot, A. Bonehill, and J. L. Aerts, Dendritic Cells: Subtypes, Life Cycle, Activation, Biological Functions and their Exploitation in Cancer Immunotherapy, 2010.
  16. A. Mildner and S. Jung, “Development and function of dendritic cell subsets,” Immunity, vol. 40, no. 5, pp. 642–656, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. A. K. Palucka, H. Ueno, J. Fay, and J. Banchereau, “Dendritic cells: a critical player in cancer therapy?” Journal of Immunotherapy, vol. 31, no. 9, pp. 793–805, 2008. View at Publisher · View at Google Scholar
  18. D. Hawiger, K. Inaba, Y. Dorsett et al., “Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo,” Journal of Experimental Medicine, vol. 194, no. 6, pp. 769–779, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. D. K. Banerjee, M. V. Dhodapkar, E. Matayeva, R. M. Steinman, and K. M. Dhodapkar, “Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients,” Blood, vol. 108, no. 8, pp. 2655–2661, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. A. L. Blasius and B. Beutler, “Intracellular toll-like receptors,” Immunity, vol. 32, no. 3, pp. 305–315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Kawai and S. Akira, “Toll-like receptor and RIG-1-like receptor signaling,” Annals of the New York Academy of Sciences, vol. 1143, pp. 1–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. G. M. Barton and J. C. Kagan, “A cell biological view of Toll-like receptor function: regulation through compartmentalization,” Nature Reviews Immunology, vol. 9, no. 8, pp. 535–542, 2009. View at Publisher · View at Google Scholar
  23. T. B. H. Geijtenbeek and S. I. Gringhuis, “Signalling through C-type lectin receptors: shaping immune responses,” Nature Reviews Immunology, vol. 9, no. 7, pp. 465–479, 2009. View at Publisher · View at Google Scholar
  24. K. Breckpot and D. Escors, “Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification,” Endocrine, Metabolic and Immune Disorders—Drug Targets, vol. 9, no. 4, pp. 328–343, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Onai, A. Obata-Onai, M. A. Schmid, T. Ohteki, D. Jarrossay, and M. G. Manz, “Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow,” Nature Immunology, vol. 8, no. 11, pp. 1207–1216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Guilliams, F. Ginhoux, C. Jakubzick et al., “Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny,” Nature Reviews Immunology, vol. 14, no. 8, pp. 571–578, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. H. S. Ghosh, B. Cisse, A. Bunin, K. L. Lewis, and B. Reizis, “Continuous expression of the transcription factor e2-2 maintains the cell fate of mature plasmacytoid dendritic cells,” Immunity, vol. 33, no. 6, pp. 905–916, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Schlitzer and F. Ginhoux, “Organization of the mouse and human DC network,” Current Opinion in Immunology, vol. 26, pp. 90–99, 2014. View at Publisher · View at Google Scholar
  29. C.-A. Dutertre, L.-F. Wang, and F. Ginhoux, “Aligning bona fide dendritic cell populations across species,” Cellular Immunology, vol. 291, no. 1-2, pp. 3–10, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. G. T. Belz and S. L. Nutt, “Transcriptional programming of the dendritic cell network,” Nature Reviews Immunology, vol. 12, no. 2, pp. 101–113, 2012. View at Publisher · View at Google Scholar
  31. L. Chorro, A. Sarde, M. Li et al., “Langerhans cell (LC) proliferation mediates neonatal development, homeostasis, and inflammation-associated expansion of the epidermal LC network,” The Journal of Experimental Medicine, vol. 206, no. 13, pp. 3089–3100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. F. P. Siegal, N. Kadowaki, M. Shodell et al., “The nature of the principal type 1 interferon-producing cells in human blood,” Science, vol. 284, no. 5421, pp. 1835–1837, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Cheong, I. Matos, J.-H. Choi et al., “Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209+ dendritic cells for immune T cell areas,” Cell, vol. 143, no. 3, pp. 416–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Klechevsky and J. Banchereau, “Human dendritic cells subsets as targets and vectors for therapy,” Annals of the New York Academy of Sciences, vol. 1284, no. 1, pp. 24–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Haniffa, A. Shin, V. Bigley et al., “Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells,” Immunity, vol. 37, no. 1, pp. 60–73, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Shortman and W. R. Heath, “The CD8+ dendritic cell subset,” Immunological Reviews, vol. 234, no. 1, pp. 18–31, 2010. View at Publisher · View at Google Scholar
  37. M. Semmrich, M. Plantinga, M. Svensson-Frej et al., “Directed antigen targeting in vivo identifies a role for CD103+ dendritic cells in both tolerogenic and immunogenic T-cell responses,” Mucosal Immunology, vol. 5, no. 2, pp. 150–160, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Meixlsperger, C. S. Leung, P. C. Rämer et al., “CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice,” Blood, vol. 121, no. 25, pp. 5034–5044, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. M. L. Broz, M. Binnewies, B. Boldajipour et al., “Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity,” Cancer Cell, vol. 26, no. 5, pp. 638–652, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Kastenmüller, K. Kastenmüller, C. Kurts, and R. A. Seder, “Dendritic cell-targeted vaccines—hope or hype?” Nature Reviews Immunology, vol. 14, no. 10, pp. 705–711, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Palucka, J. Banchereau, and I. Mellman, “Designing vaccines based on biology of human dendritic cell subsets,” Immunity, vol. 33, no. 4, pp. 464–478, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Hochrein, M. O'Keeffe, and H. Wagner, “Human and mouse plasmacytoid dendritic cells,” Human Immunology, vol. 63, no. 12, pp. 1103–1110, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Tel, E. H. J. G. Aarntzen, T. Baba, and et al, “Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients,” Cancer Research, vol. 73, no. 3, pp. 1063–1075, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Palucka, H. Ueno, L. Roberts, J. Fay, and J. Banchereau, “Dendritic cell subsets as vectors and targets for improved cancer therapy,” Current Topics In Microbiology and Immunology, vol. 344, pp. 173–192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Goyvaerts, D. G. Kurt, S. Van Lint et al., “Immunogenicity of targeted lentivectors,” Oncotarget, vol. 5, no. 3, pp. 704–715, 2014. View at Google Scholar · View at Scopus
  46. S. Van Lint, D. Renmans, K. Broos et al., “The ReNAissanCe of mRNA-based cancer therapy,” Expert Review of Vaccines, vol. 14, no. 2, pp. 235–251, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. Z. Amoozgar and M. S. Goldberg, “Targeting myeloid cells using nanoparticles to improve cancer immunotherapy,” Advanced Drug Delivery Reviews, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Dewitte, R. Verbeke, K. Breckpot, S. C. De Smedt, and I. Lentacker, “Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment,” Nano Today, vol. 9, no. 6, pp. 743–758, 2014. View at Publisher · View at Google Scholar
  49. M. Dullaers, S. Van Meirvenne, C. Heirman et al., “Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors,” Gene Therapy, vol. 13, no. 7, pp. 630–640, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Chapatte, S. Colombetti, J.-C. Cerottini, and F. Lévy, “Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors,” Cancer Research, vol. 66, no. 2, pp. 1155–1160, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Rusakiewicz, M. Dosset, K. Mollier et al., “Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B0702 transgenic mice,” Vaccine, vol. 28, no. 38, pp. 6374–6381, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Van Lint, C. Goyvaerts, S. Maenhout et al., “Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy,” Cancer Research, vol. 72, no. 7, pp. 1661–1671, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. I. C. Kourtis, S. Hirosue, A. de Titta et al., “Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice,” PLoS ONE, vol. 8, no. 4, Article ID e61646, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Wang, P. Liu, Y. Zhuang et al., “Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory,” Vaccine, vol. 32, no. 42, pp. 5475–5483, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. N. K. Kunda, I. M. Alfagih, S. R. Dennison et al., “Bovine serum albumin adsorbed PGA-co-PDL nanocarriers for vaccine delivery via dry powder inhalation,” Pharmaceutical Research, vol. 32, no. 4, pp. 1341–1353, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. S. N. Thomas, E. Vokali, A. W. Lund, J. A. Hubbell, and M. A. Swartz, “Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response,” Biomaterials, vol. 35, no. 2, pp. 814–824, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Jeanbart, M. Ballester, A. de Titta et al., “Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes,” Cancer Immunology Research, vol. 2, no. 5, pp. 436–447, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Dewitte, S. Van Lint, C. Heirman et al., “The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy,” Journal of Controlled Release, vol. 194, pp. 28–36, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Zaric, O. Lyubomska, C. Poux et al., “Dissolving microneedle delivery of nanoparticle-encapsulated antigen elicits efficient cross-priming and Th1 immune responses by murine langerhans cells,” Journal of Investigative Dermatology, vol. 135, no. 2, pp. 425–434, 2014. View at Publisher · View at Google Scholar
  60. M. Zaric, O. Lyubomska, O. Touzelet et al., “Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-d,l-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses,” ACS Nano, vol. 7, no. 3, pp. 2042–2055, 2013. View at Publisher · View at Google Scholar
  61. K. Van der Jeught, L. Bialkowski, L. Daszkiewicz et al., “Targeting the tumor microenvironment to enhance antitumor immune responses,” Oncotarget, vol. 6, no. 3, pp. 1359–1381, 2015. View at Google Scholar · View at Scopus
  62. S. A. Rosenberg, R. M. Sherry, K. E. Morton et al., “Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma,” The Journal of Immunology, vol. 175, no. 9, pp. 6169–6176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. A. A. Keskinov and M. R. Shurin, “Myeloid regulatory cells in tumor spreading and metastasis,” Immunobiology, vol. 220, pp. 236–242, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. J. M. T. Janco, P. Lamichhane, L. Karyampudi, and K. L. Knutson, “Tumor-infiltrating dendritic cells in cancer pathogenesis,” The Journal of Immunology, vol. 194, no. 7, pp. 2985–2991, 2015. View at Publisher · View at Google Scholar
  65. S. Kim, G. J. Kim, H. Miyoshi et al., “Efficiency of the elongation factor-1alpha promoter in mammalian embryonic stem cells using lentiviral gene delivery systems,” Stem Cells and Development, vol. 16, no. 4, pp. 537–545, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. D. E. Gilham, M. Lie-A-Ling, N. Taylor, and R. E. Hawkins, “Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction of mouse T cells with HIV-1 vectors,” The Journal of Gene Medicine, vol. 12, no. 2, pp. 129–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Li, N. Husic, Y. Lin et al., “Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells,” Journal of Neuroscience Methods, vol. 189, no. 1, pp. 56–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. B. H. Liu, X. Wang, Y. X. Ma, and S. Wang, “CMV enhancer/human PDGF-β promoter for neuron-specific transgene expression,” Gene Therapy, vol. 11, no. 1, pp. 52–60, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Stein, M. G. Ott, S. Schultze-Strasser et al., “Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease,” Nature Medicine, vol. 16, no. 2, pp. 198–204, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. F. Di Nunzio, G. Maruggi, S. Ferrari et al., “Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors,” Molecular Therapy, vol. 16, no. 12, pp. 1977–1985, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Cao, K. Sodhi, K. Inoue et al., “Lentiviral-human heme oxygenase targeting endothelium improved vascular function in angiotensin II animal model of hypertension,” Human Gene Therapy, vol. 22, no. 3, pp. 271–282, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Lopes, M. Dewannieux, U. Gileadi et al., “Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses,” Journal of Virology, vol. 82, no. 1, pp. 86–95, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Cui, J. Golob, E. Kelleher, Z. Ye, D. Pardoll, and L. Cheng, “Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells,” Blood, vol. 99, no. 2, pp. 399–408, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Pincha, G. Salguero, D. Wedekind et al., “Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells,” Gene Therapy, vol. 18, no. 8, pp. 750–764, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. V. Moulin, M. E. Morgan, D. Eleveld-Trancikova et al., “Targeting dendritic cells with antigen via dendritic cell-associated promoters,” Cancer Gene Therapy, vol. 19, no. 5, pp. 303–311, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Dresch, S. L. Edelmann, P. Marconi, and T. Brocker, “Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo,” Journal of Immunology, vol. 181, no. 7, pp. 4495–4506, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. B. De Andrade Pereira, C. Fraefel, M. Hilbe, M. Ackermann, and C. Dresch, “Transcriptional targeting of DCs with lentiviral vectors induces antigen-specific tolerance in a mouse model of multiple sclerosis,” Gene Therapy, vol. 20, no. 5, pp. 556–566, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. M. De Palma, E. Montini, F. R. Santoni De Sio et al., “Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells,” Blood, vol. 105, no. 6, pp. 2307–2315, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Schambach, D. Zychlinski, B. Ehrnstroem, and C. Baum, “Biosafety features of lentiviral vectors,” Human Gene Therapy, vol. 24, no. 2, pp. 132–142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. B. Barrilleaux and P. Knoepfler, “Transduction of human cells with polymer-complexed ecotropic lentivirus for enhanced biosafety,” Journal of Visualized Experiments, no. 53, 2011. View at Publisher · View at Google Scholar
  81. C. G. Park, “Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivo,” Clinical and Experimental Vaccine Research, vol. 3, no. 2, pp. 149–154, 2014. View at Publisher · View at Google Scholar
  82. I. Streng-Ouwehand, W. W. J. Unger, and Y. Van Kooyk, “C-type lectin receptors for tumor eradication: future directions,” Cancers, vol. 3, no. 3, pp. 3169–3188, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. C. L. Van Broekhoven, C. R. Parish, C. Demangel, W. J. Britton, and J. G. Altin, “Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy,” Cancer Research, vol. 64, no. 12, pp. 4357–4365, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. Liu, A. Tai, K.-I. Joo, and P. Wang, “Visualization of DC-SIGN-mediated entry pathway of engineered lentiviral vectors in target cells,” PLoS ONE, vol. 8, no. 6, Article ID e67400, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. D. Li, G. Romain, A.-L. Flamar et al., “Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells,” Journal of Experimental Medicine, vol. 209, no. 1, pp. 109–121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Bachem, E. Hartung, S. Güttler et al., “Expression of XCR1 characterizes the Batf3-dependent lineage of dendritic cells capable of antigen cross-presentation,” Frontiers in Immunology, vol. 3, article 214, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Bachem, S. Güttler, E. Hartung et al., “Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells,” Journal of Experimental Medicine, vol. 207, no. 6, pp. 1273–1281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. K. M. Tullett, M. H. Lahoud, and K. J. Radford, “Harnessing human cross-presenting CLEC9A+XCR1+ dendritic cells for immunotherapy,” Frontiers in Immunology, vol. 5, article 239, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. D. V. Schaffer, J. T. Koerber, and K. Lim, “Molecular engineering of viral gene delivery vehicles,” Annual Review of Biomedical Engineering, vol. 10, no. 1, pp. 169–194, 2008. View at Publisher · View at Google Scholar
  90. M. Sioud, G. Skorstad, A. Mobergslien, and S. Sæbøe-Larssen, “A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells,” The FASEB Journal, vol. 27, no. 8, pp. 3272–3283, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. G. H. Guibinga, F. L. Hall, E. M. Gordon, E. Ruoslahti, and T. Friedmann, “Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype,” Molecular Therapy, vol. 9, no. 1, pp. 76–84, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. D. Lavillette, S. J. Russell, and F.-L. Cosset, “Retargeting gene delivery using surface-engineered retroviral vector particles,” Current Opinion in Biotechnology, vol. 12, no. 5, pp. 461–466, 2001. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Katane, E. Takao, Y. Kubo, R. Fujita, and H. Amanuma, “Factors affecting the direct targeting of murine leukemia virus vectors containing peptide ligands in the envelope protein,” EMBO Reports, vol. 3, no. 9, pp. 899–904, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. G. Karavanas, M. Marin, E. Bachrach, A. G. Papavassiliou, and M. Piechaczyk, “The insertion of an anti-MHC I ScFv into the N-terminus of an ecotropic MLV glycoprotein does not alter its fusiogenic potential on murine cells,” Virus Research, vol. 83, no. 1-2, pp. 57–69, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. B. C. Wengerter, J. A. Katakowski, J. M. Rosenberg et al., “Aptamer-targeted antigen delivery,” Molecular Therapy, vol. 22, no. 7, pp. 1375–1387, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. R. C. Münch, M. D. Mühlebach, T. Schaser et al., “DARPins: an efficient targeting domain for lentiviral vectors,” Molecular Therapy, vol. 19, no. 4, pp. 686–693, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. C. Hamers-Casterman, T. Atarhouch, S. Muyldermans et al., “Naturally occurring antibodies devoid of light chains,” Nature, vol. 363, no. 6428, pp. 446–448, 1993. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Muyldermans, “Nanobodies: natural single-domain antibodies,” Annual Review of Biochemistry, vol. 82, no. 1, pp. 775–797, 2013. View at Publisher · View at Google Scholar
  99. I. Vaneycken, M. D'huyvetter, S. Hernot et al., “Immuno-imaging using nanobodies,” Current Opinion in Biotechnology, vol. 22, no. 6, pp. 877–881, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. J. De Vos, N. Devoogdt, T. Lahoutte, and S. Muyldermans, “Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target,” Expert Opinion on Biological Therapy, vol. 13, no. 8, pp. 1149–1160, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. K. Movahedi, S. Schoonooghe, D. Laoui et al., “Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages,” Cancer Research, vol. 72, no. 16, pp. 4165–4177, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. K. De Groeve, N. Deschacht, C. De Koninck et al., “Nanobodies as tools for in vivo imaging of specific immune cell types,” Journal of Nuclear Medicine, vol. 51, no. 5, pp. 782–789, 2010. View at Publisher · View at Google Scholar
  103. L. Xiao, K.-I. Joo, M. Lim, and P. Wang, “Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice,” PloS ONE, vol. 7, no. 11, Article ID e48866, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. B. Hu, B. Dai, and P. Wang, “Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity,” Vaccine, vol. 28, no. 41, pp. 6675–6683, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. B. Dai, L. Yang, H. Yang, B. Hu, D. Baltimore, and P. Wang, “HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20382–20387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. V. Karanikas, L.-A. Hwang, J. Pearson et al., “Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein,” The Journal of Clinical Investigation, vol. 100, no. 11, pp. 2783–2792, 1997. View at Publisher · View at Google Scholar · View at Scopus
  107. M. A. Croyle, S. M. Callahan, A. Auricchio et al., “PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum,” Journal of Virology, vol. 78, no. 2, pp. 912–921, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. J.-C. Zeng, Z. Zhang, T.-Y. Li et al., “Assessing the role of IL-35 in colorectal cancer progression and prognosis,” International Journal of Clinical and Experimental Pathology, vol. 6, no. 9, pp. 1806–1816, 2013. View at Google Scholar
  109. C. J. Buchholz, L. J. Duerner, S. Funke, and I. C. Schneider, “Retroviral display and high throughput screening,” Combinatorial Chemistry and High Throughput Screening, vol. 11, no. 2, pp. 99–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. C. Metzner, F. Kochan, and J. A. Dangerfield, “Postexit surface engineering of retroviral/lentiviral vectors,” BioMed Research International, vol. 2013, Article ID 253521, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. C. Goyvaerts, J. Dingemans, K. De Groeve et al., “Targeting of human antigen-presenting cell subsets,” Journal of Virology, vol. 87, no. 20, pp. 11304–11308, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. S. Ciré, S. Da Rocha, R. Yao et al., “Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo,” PLoS ONE, vol. 9, no. 7, Article ID e101644, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. G. Dadaglio, C. Fayolle, X. Zhang et al., “Antigen targeting to CD11b+ dendritic cells in association with TLR4/TRIF signaling promotes strong CD8+ T cell responses,” Journal of Immunology, vol. 193, no. 4, pp. 1787–1798, 2014. View at Publisher · View at Google Scholar · View at Scopus
  114. M. M. Seavey, Z.-K. Pan, P. C. Maciag et al., “A novel human Her-2/neu chimeric molecule expressed by listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors,” Clinical Cancer Research, vol. 15, no. 3, pp. 924–932, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. D. T. Le, T. W. Dubenksy Jr., and D. G. Brockstedt, “Clinical development of listeria monocytogenes-based immunotherapies,” Seminars in Oncology, vol. 39, no. 3, pp. 311–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. C. S. Leung, M. A. Maurer, S. Meixlsperger et al., “Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205,” Blood, vol. 121, no. 9, pp. 1584–1594, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. M. D. Joshi, W. J. Unger, G. Storm, Y. Van Kooyk, and E. Mastrobattista, “Targeting tumor antigens to dendritic cells using particulate carriers,” Journal of Controlled Release, vol. 161, no. 1, pp. 25–37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Maglinao, M. Eriksson, M. K. Schlegel et al., “A platform to screen for C-type lectin receptor-binding carbohydrates and their potential for cell-specific targeting and immune modulation,” Journal of Controlled Release, vol. 175, no. 1, pp. 36–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Kreutz, P. J. Tacken, and C. G. Figdor, “Targeting dendritic cells—why bother?” Blood, vol. 121, no. 15, pp. 2836–2844, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. M. Kreutz, B. Giquel, Q. Hu et al., “Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity,” PLoS ONE, vol. 7, no. 7, Article ID e40208, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. L. J. Thomann-Harwood, P. Kaeuper, N. Rossi, P. Milona, B. Herrmann, and K. C. McCullough, “Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation,” Journal of Controlled Release, vol. 166, no. 2, pp. 95–105, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. L. E. Ruff, E. A. Mahmoud, J. Sankaranarayanan et al., “Antigen-loaded pH-sensitive hydrogel microparticles are taken up by dendritic cells with no requirement for targeting antibodies,” Integrative Biology, vol. 5, no. 1, pp. 195–203, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Reuter, S. E. Panozza, C. Macri et al., “Criteria for dendritic cell receptor selection for efficient antibody-targeted vaccination,” The Journal of Immunology, vol. 194, no. 6, pp. 2696–2705, 2015. View at Publisher · View at Google Scholar
  124. L.-Z. He, J. Weidlick, C. Sisson, H. C. Marsh, and T. Keler, “Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine,” Cellular and Molecular Immunology, 2014. View at Publisher · View at Google Scholar
  125. J.-S. Thomann, B. Heurtault, S. Weidner et al., “Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting,” Biomaterials, vol. 32, no. 20, pp. 4574–4583, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. A. C. Armstrong and D. E. Gilham, “Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?” Breast Cancer Research, vol. 14, article 106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  127. M. Tenbusch, G. Nchinda, M. S. G. Bonsmann, V. Temchura, and K. Überla, “Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response,” International Immunology, vol. 25, no. 4, pp. 247–258, 2013. View at Publisher · View at Google Scholar · View at Scopus
  128. I. Caminschi, E. Maraskovsky, and W. R. Heath, “Targeting dendritic cells in vivo for cancer therapy,” Frontiers in Immunology, vol. 3, article 13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  129. S. Basta and A. Alatery, “The cross-priming pathway: a portrait of an intricate immune system,” Scandinavian Journal of Immunology, vol. 65, no. 4, pp. 311–319, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. P. J. Tacken, I. S. Zeelenberg, L. J. Cruz et al., “Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity,” Blood, vol. 118, no. 26, pp. 6836–6844, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. L. C. Bonifaz, D. P. Bonnyay, A. Charalambous et al., “In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination,” Journal of Experimental Medicine, vol. 199, no. 6, pp. 815–824, 2004. View at Publisher · View at Google Scholar · View at Scopus
  132. J. Idoyaga, A. Lubkin, C. Fiorese et al., “Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 6, pp. 2384–2389, 2011. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Tel, S. P. Sittig, R. A. M. Blom et al., “Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion,” The Journal of Immunology, vol. 191, no. 10, pp. 5005–5012, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. K. J. Radford, K. M. Tullett, and M. H. Lahoud, “Dendritic cells and cancer immunotherapy,” Current Opinion in Immunology, vol. 27, no. 1, pp. 26–32, 2014. View at Publisher · View at Google Scholar · View at Scopus
  135. C. P. Chappell, N. V. Giltiay, C. Dresch, and E. A. Clark, “Controlling immune responses by targeting antigens to dendritic cell subsets and B cells,” International Immunology, vol. 26, no. 1, pp. 3–11, 2014. View at Publisher · View at Google Scholar · View at Scopus
  136. R. Maldonado-López, T. De Smedt, P. Michel et al., “CD8α+ and CD8α subclasses of dendritic cells direct the development of distinct T helper cells in vivo,” Journal of Experimental Medicine, vol. 189, no. 3, pp. 587–592, 1999. View at Publisher · View at Google Scholar · View at Scopus
  137. C.-C. Chu, N. Ali, P. Karagiannis et al., “Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation,” Journal of Experimental Medicine, vol. 209, no. 5, pp. 935–945, 2012. View at Publisher · View at Google Scholar · View at Scopus
  138. D. Sancho, D. Mourão-Sá, O. P. Joffre et al., “Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin,” Journal of Clinical Investigation, vol. 118, no. 6, pp. 2098–2110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  139. O. P. Joffre, D. Sancho, S. Zelenay, A. M. Keller, and C. Reis e Sousa, “Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A,” European Journal of Immunology, vol. 40, no. 5, pp. 1255–1265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  140. V. Apostolopoulos, G. A. Pietersz, A. Tsibanis et al., “Dendritic cell immunotherapy: clinical outcomes,” Clinical & Translational Immunology, vol. 3, no. 7, article e21, 2014. View at Publisher · View at Google Scholar
  141. K. Kobiyama, T. Aoshi, H. Narita et al., “Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 8, pp. 3086–3091, 2014. View at Publisher · View at Google Scholar · View at Scopus
  142. L. Cohn and L. Delamarre, “Dendritic cell-targeted vaccines,” Frontiers in Immunology, vol. 5, article 255, 2014. View at Publisher · View at Google Scholar
  143. K. Kastenmüller, U. Wille-Reece, R. W. B. Lindsay et al., “Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets,” The Journal of Clinical Investigation, vol. 121, no. 5, pp. 1782–1796, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. K. Sehgal, R. Ragheb, T. M. Fahmy, M. V. Dhodapkar, and K. M. Dhodapkar, “Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk,” Journal of Immunology, vol. 193, no. 5, pp. 2297–2305, 2014. View at Publisher · View at Google Scholar · View at Scopus
  145. F. Wimmers, G. Schreibelt, A. E. Sköld, C. G. Figdor, and I. J. M. De Vries, “Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets,” Frontiers in Immunology, vol. 5, article 165, 2014. View at Publisher · View at Google Scholar · View at Scopus
  146. G. Grødeland, S. Mjaaland, G. Tunheim, A. B. Fredriksen, and B. Bogen, “The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype,” PLoS ONE, vol. 8, no. 11, Article ID e80008, 2013. View at Publisher · View at Google Scholar · View at Scopus
  147. E. Macho-Fernandez, L. J. Cruz, R. Ghinnagow et al., “Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses,” Journal of Immunology, vol. 193, no. 2, pp. 961–969, 2014. View at Publisher · View at Google Scholar · View at Scopus
  148. B. Wang, “Targeting dendritic cells in situ for breast cancer immunotherapy,” OncoImmunology, vol. 1, no. 8, pp. 1398–1400, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. B. Wang, N. Zaidi, L.-Z. He et al., “Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice,” Breast Cancer Research, vol. 14, no. 2, article R39, 2012. View at Publisher · View at Google Scholar · View at Scopus
  150. B. Wang, J. M. Y. Kuroiwa, L.-Z. He, A. Charalambous, T. Keler, and R. M. Steinman, “The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells,” Annals of the New York Academy of Sciences, vol. 1174, pp. 6–17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. R. Sartorius, C. Bettua, L. D'Apice et al., “Vaccination with filamentous bacteriophages targeting DEC-205 induces DC maturation and potent anti-tumor T-cell responses in the absence of adjuvants,” European Journal of Immunology, vol. 41, no. 9, pp. 2573–2584, 2011. View at Publisher · View at Google Scholar · View at Scopus
  152. K. Mahnke, Y. Qian, S. Fondel, J. Brueck, C. Becker, and A. H. Enk, “Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice,” Cancer Research, vol. 65, no. 15, pp. 7007–7012, 2005. View at Publisher · View at Google Scholar · View at Scopus
  153. J. Cao, Y. Jin, W. Li et al., “DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice,” BMC Immunology, vol. 14, article 39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  154. M. V. Dhodapkar, M. Sznol, B. Zhao et al., “Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205,” Science Translational Medicine, vol. 6, no. 232, Article ID 232ra51, 2014. View at Publisher · View at Google Scholar · View at Scopus
  155. J. M. Silva, E. Zupancic, G. Vandermeulen et al., “In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model,” Journal of Controlled Release, vol. 198, pp. 91–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  156. L.-Z. He, A. Crocker, J. Lee et al., “Antigenic targeting of the human mannose receptor induces tumor immunity,” Journal of Immunology, vol. 178, no. 10, pp. 6259–6267, 2007. View at Publisher · View at Google Scholar · View at Scopus
  157. V. Apostolopoulos, G. A. Pietersz, and I. F. C. McKenzie, “Cell-mediated immune responses to MUC1 fusion protein coupled to mannan,” Vaccine, vol. 14, no. 9, pp. 930–938, 1996. View at Publisher · View at Google Scholar · View at Scopus
  158. K.-C. Sheng, M. Kalkanidis, D. S. Pouniotis et al., “Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo,” European Journal of Immunology, vol. 38, no. 2, pp. 424–436, 2008. View at Publisher · View at Google Scholar · View at Scopus
  159. Z. Cui, S.-J. Han, and L. Huang, “Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor,” Pharmaceutical Research, vol. 21, no. 6, pp. 1018–1025, 2004. View at Publisher · View at Google Scholar · View at Scopus
  160. F. Perche, T. Benvegnu, M. Berchel et al., “Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 7, no. 4, pp. 445–453, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. M. Mockey, E. Bourseau, V. Chandrashekhar et al., “mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes,” Cancer Gene Therapy, vol. 14, no. 9, pp. 802–814, 2007. View at Publisher · View at Google Scholar · View at Scopus
  162. H. Shiku, L. Wang, Y. Ikuta et al., “Development of a cancer vaccine: peptides, proteins, and DNA,” Cancer Chemotherapy and Pharmacology, vol. 46, supplement, pp. S77–S82, 2000. View at Publisher · View at Google Scholar · View at Scopus
  163. P. M. Moyle, C. Olive, M.-F. Ho et al., “Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines,” Journal of Medicinal Chemistry, vol. 50, no. 19, pp. 4721–4727, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. M. A. Morse, R. Chapman, J. Powderly et al., “Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor stimulation to induce immunity to self-antigens in cancer patients,” Clinical Cancer Research, vol. 17, no. 14, pp. 4844–4853, 2011. View at Publisher · View at Google Scholar · View at Scopus
  165. B. Hu, H. Yang, B. Dai, A. Tai, and P. Wang, “Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity,” Human Gene Therapy, vol. 20, no. 12, pp. 1652–1664, 2009. View at Publisher · View at Google Scholar · View at Scopus
  166. A. Kretz-Rommel, F. Qin, N. Dakappagari et al., “In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models,” Journal of Immunotherapy, vol. 30, no. 7, pp. 715–726, 2007. View at Publisher · View at Google Scholar · View at Scopus
  167. J. M. Odegard, B. Kelley-Clarke, S. U. Tareen et al., “Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy,” Journal of Immunotherapy, vol. 38, no. 2, pp. 41–53, 2015. View at Publisher · View at Google Scholar · View at Scopus
  168. S. U. Tareen, B. Kelley-Clarke, C. J. Nicolai et al., “Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells,” Molecular Therapy, vol. 22, no. 3, pp. 575–587, 2014. View at Publisher · View at Google Scholar · View at Scopus
  169. Y. Delneste, G. Magistrelli, J.-F. Gauchat et al., “Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation,” Immunity, vol. 17, no. 3, pp. 353–362, 2002. View at Publisher · View at Google Scholar · View at Scopus
  170. G. Picco, R. Beatson, J. Taylor-Papadimitriou, and J. M. Burchell, “Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas,” European Journal of Immunology, vol. 44, no. 7, pp. 1947–1955, 2014. View at Publisher · View at Google Scholar · View at Scopus
  171. K. Neubert, C. H. K. Lehmann, L. Heger et al., “Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo,” Journal of Immunology, vol. 192, no. 12, pp. 5830–5838, 2014. View at Publisher · View at Google Scholar · View at Scopus
  172. T. Akazawa, T. Ohashi, H. Nakajima et al., “Development of a dendritic cell-targeting lipopeptide as an immunoadjuvant that inhibits tumor growth without inducing local inflammation,” International Journal of Cancer, vol. 135, no. 12, pp. 2847–2856, 2014. View at Publisher · View at Google Scholar · View at Scopus
  173. A. Faham and J. G. Altin, “Ag-bearing liposomes engrafted with peptides that interact with CD11c/CD18 induce potent Ag-specific and antitumor immunity,” International Journal of Cancer, vol. 129, no. 6, pp. 1391–1403, 2011. View at Publisher · View at Google Scholar · View at Scopus
  174. X. Préville, D. Ladant, B. Timmerman, and C. Leclerc, “Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein,” Cancer Research, vol. 65, no. 2, pp. 641–649, 2005. View at Google Scholar · View at Scopus
  175. S. N. Furlan, R. Mandraju, T. Brewer et al., “Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors,” mAbs, vol. 6, no. 1, pp. 108–118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  176. I. G. Zizzari, F. Veglia, F. Taurino et al., “HER2-based recombinant immunogen to target DCs through Fc γRs for cancer immunotherapy,” Journal of Molecular Medicine, vol. 89, no. 12, pp. 1231–1240, 2011. View at Publisher · View at Google Scholar · View at Scopus
  177. P. Daftarian, A. E. Kaifer, W. Li et al., “Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells,” Cancer Research, vol. 71, no. 24, pp. 7452–7462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  178. A. Ageichik, C. J. Buchholz, and M. K. Collins, “Lentiviral vectors targeted to MHC II are effective in immunization,” Human Gene Therapy, vol. 22, no. 10, pp. 1249–1254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  179. F. Gennari, L. Lopes, E. Verhoeyen, W. Marasco, and M. K. Collins, “Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells,” Human Gene Therapy, vol. 20, no. 6, pp. 554–562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  180. A. B. Fredriksen, I. Sandlie, and B. Bogen, “Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells,” Frontiers in Oncology, vol. 2, article 154, 2012. View at Publisher · View at Google Scholar
  181. M. Frøyland, P. A. Ruffini, K. M. Thompson, T. Gedde-Dahl, A. B. Fredriksen, and B. Bogen, “Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing,” European Journal of Haematology, vol. 86, no. 5, pp. 385–395, 2011. View at Publisher · View at Google Scholar · View at Scopus
  182. J. Loschko, A. Schlitzer, D. Dudziak et al., “Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cell-mediated immunity,” The Journal of Immunology, vol. 186, no. 12, pp. 6718–6725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  183. D. Muraoka, N. Harada, T. Hayashi et al., “Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity,” ACS Nano, vol. 8, no. 9, pp. 9209–9218, 2014. View at Publisher · View at Google Scholar
  184. L. M. Wood and Y. Paterson, “Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy,” Frontiers in Cellular and Infection Microbiology, vol. 4, article 51, 2014. View at Publisher · View at Google Scholar
  185. C. Perez-Shibayama, C. Gil-Cruz, M. Nussbacher et al., “Dendritic cell-specific delivery of flt3l by coronavirus vectors secures induction of therapeutic antitumor immunity,” PLoS ONE, vol. 8, no. 11, Article ID e81442, 2013. View at Publisher · View at Google Scholar · View at Scopus
  186. L. Cervantes-Barragan, R. Züst, R. Maier et al., “Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity,” mBio, vol. 1, no. 4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  187. P. Duewell, U. Kisser, K. Heckelsmiller et al., “ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells,” Journal of Immunology, vol. 187, no. 1, pp. 55–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  188. R. A. Rosalia, L. J. Cruz, S. van Duikeren et al., “CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses,” Biomaterials, vol. 40, pp. 88–97, 2015. View at Publisher · View at Google Scholar · View at Scopus
  189. B. J. Williams, S. Bhatia, L. K. Adams et al., “Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector,” PLoS ONE, vol. 7, no. 10, Article ID e46981, 2012. View at Publisher · View at Google Scholar · View at Scopus
  190. B. N. Hangalapura, D. Oosterhoff, J. de Groot et al., “Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine,” Cancer Research, vol. 71, no. 17, pp. 5827–5837, 2011. View at Publisher · View at Google Scholar · View at Scopus
  191. B. N. Hangalapura, D. Oosterhoff, S. Aggarwal et al., “Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus,” Journal of Immunotherapy, vol. 33, no. 7, pp. 706–715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  192. U. E. Burkhardt, A. Sloots, V. Jakobi et al., “IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells,” Cancer Immunology, Immunotherapy, vol. 61, no. 9, pp. 1473–1484, 2012. View at Publisher · View at Google Scholar · View at Scopus
  193. H. Hemmi, N. Zaidi, B. Wang et al., “Treml4, an Ig superfamily member, mediates presentation of several antigens to T cells in vivo, including protective immunity to HER2 protein,” The Journal of Immunology, vol. 188, no. 3, pp. 1147–1155, 2012. View at Publisher · View at Google Scholar · View at Scopus
  194. H. J. Cho, K. Takabayashi, P.-M. Cheng et al., “Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism,” Nature Biotechnology, vol. 18, no. 5, pp. 509–514, 2000. View at Publisher · View at Google Scholar · View at Scopus
  195. D. C. Jackson, F. L. Yuk, T. Le et al., “A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 43, pp. 15440–15445, 2004. View at Publisher · View at Google Scholar · View at Scopus
  196. A. K. Panda, “Induction of anti-tumor immunity and T-cell responses using nanodelivery systems engrafting TLR-5 ligand,” Expert Review of Vaccines, vol. 10, no. 2, pp. 155–157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  197. C. Mansilla, P. Berraondo, M. Durantez et al., “Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin,” International Journal of Cancer, vol. 131, no. 3, pp. 641–651, 2012. View at Publisher · View at Google Scholar · View at Scopus
  198. F. Aranda, D. Llopiz, N. Díaz-Valdés et al., “Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors,” Cancer Research, vol. 71, no. 9, pp. 3214–3224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  199. A. Biragyn, K. Tani, M. C. Grimm, S. Weeks, and L. W. Kwak, “Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity,” Nature Biotechnology, vol. 17, no. 3, pp. 253–258, 1999. View at Publisher · View at Google Scholar · View at Scopus
  200. E. Hartung, M. Becker, A. Bachem et al., “Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1,” The Journal of Immunology, vol. 194, no. 3, pp. 1069–1079, 2015. View at Publisher · View at Google Scholar · View at Scopus